Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care March 2008 Martin Sipkoff	The Epilepsy Battle in the War Between Brands and Generics Brand-name manufacturers and many neurologists see danger in generic substitution, but the FDA insists that the practice is safe
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
Managed Care August 2001 Steve Perlstein	Four-Tier Approach Injects Consumerism Into Drug Benefit In tying copayments closely to the actual cost of medications, Humana takes a step toward promoting awareness of resource use...
Managed Care July 2002 Thomas Kaye	Managing the Drug Benefit: One Company's Experience The pharmacy director of Blue Cross of Oklahoma shares his company's success with using three tiers and coinsurance to promote member responsibility.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Managed Care March 2008 John Carroll	Should Plans Pay Physicians To Switch Patients to Generics? The AMA calls it a kickback, but the industry sees it as just good practice to give doctors an incentive to get patients on equivalent generics
The Motley Fool September 27, 2006 Michael P. Cecil	A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Wired August 24, 2009 Steve Silberman	Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology.
The Motley Fool December 13, 2004 Brian Gorman	Which Medications Are Your Best Bets? Consumer Reports' effort to rate drugs offers a marketing lesson to pharmaceutical companies.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
Pharmaceutical Executive October 1, 2005 Wade & St. Vrain	Direct to Consumer: Perfect Package Pharmaceutical packaging can strengthen brand identity and increase patient loyalty and compliance.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Pharmaceutical Executive June 1, 2014 dos Santos & Leskin	Social Media and the In-House Counsel Social media poses a regulatory and litigation maze that must be carefully navigated by pharmaceutical companies.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
Pharmaceutical Executive June 1, 2007 Stan Bernard	Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
Fast Company Neal Ungerleider	Old People Saw White And Gold, And More Insights From A 23andMe Study Of #TheDress The maker of a popular genetics kit 23andMe has issued a new report on "The Dress," and why it appears differently to different people.
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Fast Company October 19, 2011 Rachel Z. Arndt	Generic Pharmaceutical Conference Here are five in-demand meds and their generic counterparts.
The Motley Fool October 30, 2006 Brian Lawler	Reddy, Set, Go for Earnings Growth With margins tightening, generic drug maker Dr. Reddy's Laboratories finds an Rx for success. Investors, take note.
Knowledge@Wharton	Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new study comparing average prices for pharmaceuticals in nine countries -- the US, Canada, Chile, France, Germany, Italy, Japan, Mexico and the UK -- shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the US.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
American Family Physician September 1, 2006 Gardiner & Dvorkin	Promoting Medication Adherence in Children The problem of getting children to follow a treatment regimen is widespread and is frustrating for physicians. Having the child participate in devising the plan improves adherence.
BusinessWeek January 8, 2007 Arlene Weintraub	Is Your Medicine The Real Deal? Accusations are flying that some pharmacies substitute inferior versions of drugs.
Managed Care February 2008	Medication Payment Proposal Lets Consumers Pay Annually Researchers suggest an annual license fee that would entitle consumers to a year's worth of medication for each prescription they take to manage chronic diseases, with a very small or nonexistent copayment for each monthly supply.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
The Motley Fool June 8, 2007 Brian Lawler	Lilliputian Attack on Lilly? While every investor should have some degree of exposure to pharmaceutical stocks, recent patent decisions in two of the biggest pharmaceutical drugs markets should serve as a warning of the potential litigation dangers when investing in some of the sector's giants.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.